NEOsphere Biotechnologies GmbH, a German biotechnology company pioneering high-throughput proteomics to systematically build broad and unique portfolios of novel degrader targets at scale, has entered a collaboration with Kymera Therapeutics, Inc. focused on unlocking undrugged or poorly drugged disease-causing protein targets that can be only or best addressed by Targeted Protein Degradation.   Under the agreement, NEOsphere Biotechnologies will utilize its target- and E3-agnostic platform to...